keyword
MENU ▼
Read by QxMD icon Read
search

Borderline ovarian carcinoma

keyword
https://www.readbyqxmd.com/read/28101917/imaging-in-gynecological-disease-clinical-and-ultrasound-features-of-invasive-and-non-invasive-malignant-serous-ovarian-tumors
#1
F Moro, C Baima Poma, G F Zannoni, A Vidal Urbinati, T Pasciuto, M Ludovisi, M C Moruzzi, S Carinelli, D Franchi, G Scambia, A C Testa
OBJECTIVES: To describe clinical and ultrasound features of different subclasses of malignant serous ovarian tumors according to the WHO 2014 classification. METHODS: Patients with a histological diagnosis of borderline (BOT), non-invasive and invasive low grade serous carcinomas (LGSC) and high grade serous carcinoma (HGSC), who had undergone preoperative ultrasound examination, were retrospectively identified from two ultrasound centers. The masses were described using the terms of the International Ovarian Tumor Analysis group...
January 19, 2017: Ultrasound in Obstetrics & Gynecology
https://www.readbyqxmd.com/read/28041594/malignant-and-borderline-epithelial-ovarian-tumors-in-the-pediatric-and-adolescent-population
#2
Dimitrios Nasioudis, Michail Alevizakos, Kevin Holcomb, Steven S Witkin
OBJECTIVES: Malignant and borderline ovarian tumors of epithelial origin are rarely encountered among prepubertal girls and adolescents. The aim of this population-based study was to elucidate their clinicopathological characteristics and prognosis using a multi-institutional tumor registry. STUDY DESIGN AND OUTCOMES: The National Cancer Institute's Surveillance, Epidemiology, and End Results database was accessed and a cohort of females aged <=19years old, diagnosed between 1988 and 2013 with a borderline ovarian tumor (BOT) or a malignant epithelial ovarian carcinoma (EOC) was accessed...
February 2017: Maturitas
https://www.readbyqxmd.com/read/28025670/ovarian-borderline-tumors-in-the-2014-who-classification-evolving-concepts-and-diagnostic-criteria
#3
REVIEW
Steffen Hauptmann, Katrin Friedrich, Raymond Redline, Stefanie Avril
Borderline ovarian tumors (BOT) are uncommon but not rare epithelial ovarian neoplasms, intermediate between benign and malignant categories. Since BOT were first identified >40 years ago, they have inspired controversies disproportionate to their incidence. This review discusses diagnostic criteria for the histologic subtypes of BOT, highlighting areas of diagnostic challenges, ongoing controversies, and changes in terminology implemented by the recent 2014 WHO Classification of Tumours of the Female Genital Organs...
December 27, 2016: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/28006819/better-resource-utilisation-and-quality-of-care-for-ovarian-cancer-patients-using-internet-based-pathology-review
#4
S Kommoss, F Kommoss, J Diebold, S Lax, D Schmidt, A Staebler, A du Bois, J Pfisterer
BACKGROUND: The current literature indicates that a considerable number of patients in ovarian carcinoma clinical trials have histopathological diagnoses in conflict with inclusion criteria. It has been suggested that specialised pathology review prior to randomisation should become the standard procedure in study protocols. We hypothesised that our new, internet-based high-throughput infrastructure would be capable of providing specialised pathology review within 10 working days (w.d...
December 22, 2016: British Journal of Cancer
https://www.readbyqxmd.com/read/27987343/mature-cystic-teratoma-coexisting-with-clear-cell-carcinoma-in-the-ovary
#5
Koki Shimura, Mariko Matsumoto, Takuya Sugahara, Takuro Yamamoto, Nozomi Ogiso, Yoji Urata, Tomoharu Okubo
Mature cystic teratoma (MCT) is the most common benign ovarian tumor; clear-cell carcinoma (CCC) is a relatively common malignant ovarian tumor in Japan, but there are few reports on the coexistence of MCT and CCC. Here we report a case of simultaneous MCT and CCC in the ovary and review the relevant literature. The patient was a 49-year-old woman. A 5-cm MCT was found in the left ovary on initial gynecological examination, and she was referred to hospital for treatment because it was expanding. Magnetic resonance imaging showed a multilocular cystic tumor 16 × 10 × 9...
December 17, 2016: Journal of Obstetrics and Gynaecology Research
https://www.readbyqxmd.com/read/27984374/cd56-neural-cell-adhesion-molecule-expression-in-ovarian-carcinomas-association-with-high-grade-and-advanced-stage-but-not-with-neuroendocrine-differentiation
#6
Hans-Christian Bösmüller, Philipp Wagner, Deborah Lam Pham, Anna K Fischer, Karen Greif, Christine Beschorner, Bence Sipos, Falko Fend, Annette Staebler
OBJECTIVE: Neural cell adhesion molecule (CD56) has been proposed as a potential marker for neuroendocrine differentiation in carcinomas, together with synaptophysin and chromogranin A. However, CD56 immunoreactivity by itself can be found in a broad variety of tumors, including ovarian neoplasms. CD56 has recently been suggested as a potential target for antibody-based therapy. However, for ovarian carcinoma, there is only limited data available regarding the pattern of CD56 immunoreactivity, coexpression of neuroendocrine markers, and correlation with histological types and clinical parameters...
December 15, 2016: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/27976698/epithelial-ovarian-carcinoma-diagnosis-by-desorption-electrospray-ionization-mass-spectrometry-imaging
#7
Maria Luisa Dória, James S McKenzie, Anna Mroz, David L Phelps, Abigail Speller, Francesca Rosini, Nicole Strittmatter, Ottmar Golf, Kirill Veselkov, Robert Brown, Sadaf Ghaem-Maghami, Zoltan Takats
Ovarian cancer is highly prevalent among European women, and is the leading cause of gynaecological cancer death. Current histopathological diagnoses of tumour severity are based on interpretation of, for example, immunohistochemical staining. Desorption electrospray mass spectrometry imaging (DESI-MSI) generates spatially resolved metabolic profiles of tissues and supports an objective investigation of tumour biology. In this study, various ovarian tissue types were analysed by DESI-MSI and co-registered with their corresponding haematoxylin and eosin (H&E) stained images...
December 15, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27900026/clinical-implication-of-tiam1-overexpression-in-the-prognosis-of-patients-with-serous-ovarian-carcinoma
#8
Huiwen Li, Xuelian Cui, Dingbao Chen, Yang Yang, Junjie Piao, Zhenhua Lin, Guanghai Yan, Danhua Shen
T lymphoma invasion and metastasis 1 (Tiam1), a guanine nucleotide exchange factor, was originally identified as an invasion- and metastasis-inducing gene in T lymphoma cells. High expression levels of the human Tiam1 gene have been found in numerous human malignancies, suggesting a potential role as a modifier of tumor initiation and progression. However, little is known about the status of Tiam1 in ovarian carcinoma. The present study aimed to investigate the clinicopathological significance of high Tiam1 expression in serous ovarian carcinoma...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27888800/multipoint-kras-oncogene-mutations-potentially-indicate-mucinous-carcinoma-on-the-entire-spectrum-of-mucinous-ovarian-neoplasms
#9
Yi-Ju Lee, Ming-Yung Lee, Alexandra Ruan, Chi-Kuan Chen, Hao-Ping Liu, Chau-Jong Wang, Wan-Ru Chao, Chih-Ping Han
Kras mutation is a common phenomenon in many human neoplasms. We aimed to assess the Kras mutational status along the histological continuum from normal ovaries to the development of benign, borderline and malignant ovarian mucinous neoplasms. We analyzed 41 cases of malignant, 10 cases of borderline, 7 cases of benign mucinous ovarian tumors and 7 cases of normal ovarian tissue. The prevalence of Kras mutations in the normal ovary was 0.00% (n=0/7), while the prevalence in benign, borderline and malignant mucinous neoplasms was 57...
November 18, 2016: Oncotarget
https://www.readbyqxmd.com/read/27887627/epha5-protein-a-potential-marker-for-distinguishing-histological-grade-and-prognosis-in-ovarian-serous-carcinoma
#10
Xiao Chen, Xuan Wang, Xue Wei, Jiandong Wang
BACKGROUND: Ovarian serous carcinoma (OSC) is the most common ovarian epithelial malignancy. Disregulation of Eph/ephrin signaling has been implicated in oncogenesis and tumor progression. EphA5 receptor is one of large families of Eph tyrosine kinase receptor and is documented in the development of nervous system. Till now, there is no published data about the role of EphA5 in ovarian epithelial neoplasmas. METHODS: This study aims to investigate the expression of EphA5 protein in ovarian serous carcinoma, and its relationship to clinical pathological characteristics...
November 25, 2016: Journal of Ovarian Research
https://www.readbyqxmd.com/read/27870706/evaluation-of-a-validated-biomarker-test-in-combination-with-a-symptom-index-to-predict-ovarian-malignancy
#11
Renata R Urban, Alan Smith, Kathy Agnew, Vinicius Bonato, Barbara A Goff
OBJECTIVE: This study aimed to evaluate the predictive ability of a multivariate biomarker test in combination with a symptom index (SI) to identify ovarian cancer in a cohort of women planning to undergo surgery for a pelvic mass. METHODS: This was a prospective study of patients seen at a tertiary care medical center. Following consent, patients completed an SI and preoperative serum was collected for a Food and Drug Administration-cleared multivariate biomarker test [multivariate index assay (MIA)]...
November 17, 2016: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/27852697/chromosomal-instability-in-cell-free-dna-as-a-highly-specific-biomarker-for-detection-of-ovarian-cancer-in-women-with-adnexal-masses
#12
Adriaan Vanderstichele, Pieter Busschaert, Dominiek Smeets, Chiara Landolfo, Els Van Nieuwenhuysen, Karin Leunen, Patrick Neven, Frederic Amant, Sven Mahner, Elena Ioana Braicu, Robert Zeilinger, An Coosemans, Dirk Timmerman, Diether Lambrechts, Ignace Vergote
PURPOSE: Chromosomal instability is a hallmark of ovarian cancer. Here, we explore copy number alteration (CNA) profiling in cell-free DNA as a potential biomarker to detect malignancy in patients presenting with an adnexal mass. EXPERIMENTAL DESIGN: We prospectively enrolled 68 patients with an adnexal mass, of which 57 were diagnosed with invasive or borderline carcinoma and 11 with benign disease. Cell-free DNA was extracted from plasma and analyzed by low-coverage whole-genome sequencing...
November 14, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27836204/a-nationwide-study-of-ovarian-serous-borderline-tumors-in-denmark-1978-2002-risk-of-recurrence-and-development-of-ovarian-serous-carcinoma
#13
Charlotte Gerd Hannibal, Russell Vang, Jette Junge, Kirsten Frederiksen, Robert J Kurman, Susanne K Kjaer
OBJECTIVE: Absolute risk and risk factors for recurrence and ovarian serous carcinoma following ovarian serous borderline tumors (SBTs) is not well-established. METHODS: We included all women with SBTs in Denmark, 1978-2002. Diagnoses were confirmed by centralized pathology review and classified as atypical proliferative serous tumor (APST) or noninvasive low-grade serous carcinoma (LGSC). Implants were classified as noninvasive or invasive. Medical records were collected and reviewed, and follow-up was obtained...
January 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/27823775/similar-expression-pattern-of-nherf1-and-ezrin-in-papillary-but-not-in-solid-areas-of-human-serous-ovarian-carcinomas
#14
Brenda Demacopulo, Baltazar Eduardo Lema, Rómulo Luis Cabrini, Erica Lorena Kreimann
NHERF1 is an adaptor protein expressed in the apical membrane of polarized epithelia, which interacts with the EZRIN-Radixin-Moesin (ERM) family of proteins connecting signaling pathways to the cell cytoskeleton. NHERF1 and EZRIN cooperate in the maintenance of the apical microvilli in polarized epithelial cells. In several types of cancers, NHERF1 and EZRIN are displaced from the apical compartment to the cytoplasm and nuclei of cancer cells. At the present, the distribution of NHERF1 in ovarian tumors is not well known...
October 2016: Acta Histochemica
https://www.readbyqxmd.com/read/27801762/value-of-pathology-review-in-a-population-based-series-of-ovarian-tumors
#15
Colin J R Stewart, Louise M Stewart, C D'Arcy J Holman, Susan Jordan, James Semmens, Katrina Spilsbury, Timothy Threlfall
Ovarian neoplasia comprises a heterogenous group of tumors with distinct clinicopathologic and molecular features and therefore assessment of potential risk factors should be tumor subtype specific. As part of ongoing epidemiological investigations of ovarian neoplasia in Western Australia, we performed an initial review of original pathology reports followed, in selected cases, by reassessment of histology material to optimize accurate diagnosis. Additional immunohistochemistry, often using antibodies unavailable at the time of initial assessment, was also performed as required...
October 31, 2016: International Journal of Gynecological Pathology
https://www.readbyqxmd.com/read/27798689/clinical-significance-of-tissue-factor-pathway-inhibitor-2-a-serum-biomarker-candidate-for-ovarian-clear-cell-carcinoma
#16
Noriaki Arakawa, Hiroshi Kobayashi, Naohiro Yonemoto, Yusuke Masuishi, Yoko Ino, Hiroshi Shigetomi, Naoto Furukawa, Norihisa Ohtake, Yohei Miyagi, Fumiki Hirahara, Hisashi Hirano, Etsuko Miyagi
BACKGROUND: There is currently no reliable serum biomarker for ovarian clear cell carcinoma (CCC), a highly lethal histological subtype of epithelial ovarian cancer (EOC). Previously, using a proteome-based approach, we identified tissue factor pathway inhibitor 2 (TFPI2) as a candidate serum biomarker for CCC. In this study, we sought to evaluate the clinical diagnostic performance of TFPI2 in preoperative prediction of CCC. METHODS: Serum TFPI2 levels were measured in serum samples from a retrospective training set consisting of patients with benign and borderline ovarian tumors, EOC subtypes, and uterine diseases...
2016: PloS One
https://www.readbyqxmd.com/read/27780698/management-of-borderline-ovarian-tumours
#17
REVIEW
David M Gershenson
Approximately 3000 American women are diagnosed with borderline ovarian tumours annually. Borderline tumours are similar to other types of adnexal masses. Prognostic factors include the International Federation of Gynecology and Obstetrics (FIGO) stage, presence of peritoneal implants, micropapillary pattern (for serous histology), microinvasion and intra-epithelial carcinoma (for mucinous histology). Approximately 65-70% of serous tumours and 90% of mucinous tumours are stage I, and 30% and 10%, respectively, are associated with extra-ovarian spread...
October 3, 2016: Best Practice & Research. Clinical Obstetrics & Gynaecology
https://www.readbyqxmd.com/read/27770808/p14-expression-differences-in-ovarian-benign-borderline-and-malignant-epithelial-tumors
#18
Vinicius Duarte Cabral, Marcelle Reesink Cerski, Ivana Trindade Sa Brito, Lucia Maria Kliemann
BACKGROUND: Abnormalities in tumor suppressors p14, p16 and p53 are reported in several human cancers. In ovarian epithelial carcinogenesis, p16 and p53 show higher immunohistochemical staining frequencies in malignant tumors and are associated with poor prognoses. p14 was only analyzed in carcinomas, with conflicting results. There are no reports on its expression in benign and borderline tumors. This study aims to determine p14, p16 and p53 expression frequencies in ovarian benign, borderline and malignant tumors and their associations with clinical parameters...
October 22, 2016: Journal of Ovarian Research
https://www.readbyqxmd.com/read/27759179/imaging-in-gynecological-disease-clinical-and-ultrasound-features-of-mucinous-ovarian-tumors
#19
F Moro, G F Zannoni, D Arciuolo, T Pasciuto, S Amoroso, F Mascilini, S Mainenti, G Scambia, A C Testa
OBJECTIVES: To describe clinical and ultrasound findings of mucinous ovarian tumors. METHODS: Patients with a histological diagnosis of mucinous ovarian tumor who had undergone preoperative ultrasound examination were retrospectively identified from a single ultrasound center. The histological examination was performed by the same pathologist in all cases. The masses were described using the terms and definitions of the International Ovarian Tumor Analysis group...
August 12, 2016: Ultrasound in Obstetrics & Gynecology
https://www.readbyqxmd.com/read/27685896/borderline-ovarian-tumors-a-contemporary-review-of-clinicopathological-characteristics-diagnostic-methods-and-therapeutic-options
#20
Pinar Solmaz Hasdemir, Tevfik Guvena
Borderline ovarian tumors (BOTs) differ from the epithelial ovarian malignancies with their excellent prognosis, curability with surgery, and being seen in relatively young ages. Thus, fertility sparing and conservative surgical approaches are currently recommended. Preoperative diagnosis of BOTs can be challenging because, clinical and ultrasonographic features might overlap with invasive carcinomas and sometimes with benign adnexal masses. Certain characteristics such as stage at diagnosis, age of the patient and histologic features are important while deciding the extensiveness and the type of surgery...
July 2016: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
keyword
keyword
15094
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"